Cancer Detection and Diagnosis Research in Connecticut
Cancer Detection and Diagnosis Research (93.394) awarded $35.4 million to recipients in Connecticut in 32 grants from fiscal 2021 to 2025, 1.3% of the program's national total. Yale Univ received the most, $26.9 million.
- Awarded in Connecticut$35.4 million
- Awards32
- Share of the program1.3%
- Rank among states20th of 45
- National total$2.7 billion
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 9 | $2.9 million |
| FY 2022 | 9 | $5.1 million |
| FY 2023 | 16 | $7.7 million |
| FY 2024 | 18 | $8.9 million |
| FY 2025 | 18 | $10.8 million |
Recipients in Connecticut
| Recipient | Type | Awards | Amount |
|---|---|---|---|
| Yale Univ | Colleges and universities | 22 | $26.9 million |
| University of Connecticut Health Center | Colleges and universities | 4 | $2.9 million |
| Binary Genomics, Inc | Small businesses | 2 | $2.4 million |
| Alara Imaging Inc | Small businesses | 1 | $2.0 million |
| University of Connecticut | Colleges and universities | 1 | $544,164 |
| Intus Biosciences LLC | Small businesses | 1 | $405,973 |
| Cytoveris Inc | Small businesses | 1 | $399,948 |
Open opportunities under this program
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
- Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)
- Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)
- National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
- Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)
- Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) (U24 Clinical Trial Not Allowed)
- NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
- NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
See all 50 on the program page
Questions people ask
How much Cancer Detection and Diagnosis Research money goes to Connecticut?
$35.4 million from fiscal 2021 to 2025, across 32 awards. Connecticut ranks 20th of 45 states and territories for this program.
Who receives Cancer Detection and Diagnosis Research money in Connecticut?
The largest recipient is Yale Univ, with $26.9 million in 22 awards. Next are University of Connecticut Health Center and Binary Genomics, Inc.
Can organizations in Connecticut apply now?
Yes, 50 opportunities under this program are open or forecast on Grants.gov. Federal grants are national, so eligibility depends on the notice, not the state.
Cancer Detection and Diagnosis Research in other states
Other large programs in Connecticut
- Grants to States for Medicaid
- Highway Planning and Construction
- Education Stabilization Fund
- Federal Transit Formula Grants
- Temporary Assistance for Needy Families
- National School Lunch Program
- Disaster Grants - Public Assistance (Presidentially Declared Disasters)
- USAID Foreign Assistance for Programs Overseas
- Special Education Grants to States
- Title I Grants to Local Educational Agencies